赛升药业：多位股东计划减持股份

Core Viewpoint - The company announced that its controlling shareholder and actual controller's concerted actors, Ma Li and Liu Shuqin, plan to reduce their holdings in the company by a total of no more than 9.633328 million shares, which accounts for up to 2% of the company's total share capital, due to personal funding needs [1] Summary by Relevant Sections - Share Reduction Plan - The planned share reduction will occur between October 21, 2025, and January 20, 2026 [1] - The reduction will be executed through centralized bidding and block trading methods [1] - Reason for Reduction - The primary reason for the share reduction is the personal funding needs of the shareholders [1] - Compliance - The share reduction plan complies with relevant laws and regulatory documents [1]